Molecular Predictive Pathology in Advanced Non-small Cell Lung Cancer: Next-Generation Diagnostics and Treatments

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Pathology".

Deadline for manuscript submissions: closed (25 March 2023) | Viewed by 4341

Special Issue Editors

E-Mail Website
Guest Editor
Department of Public Health, University of Naples Federico II, Naples, Italy
Interests: molecular pathology; predictive molecular pathology in solid tumors; next-generation sequencing; liquid biopsies; biomarkers; target therapies; immunotherapy
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Oncology, AOU San Luigi Gonzaga, University of Turin, Orbassano, Italy
Interests: thoracic malignancies; precision medicine; gender differences in lung cancer; clinical applied research on lung cancer and mesothelioma; targeted therapies; immunotherapy; quality of life

Special Issue Information

Dear Colleagues,

In recent years, the diagnostic and clinical management of advanced non-small cell lung cancer (NSCLC) patients has rapidly evolved. This increasing complexity is determined by the identification of novel biomarkers associated with novel targeted drugs. Thus, it is crucial to bring up-to-date healthcare personnel involved with advanced NSCLC patients on the most recent advances in the field of molecular predictive pathology and oncology in order to avoid leaving any patient behind. For this reason, this Special Issue plans to focus on both the molecular characterization and innovative molecular-based targeted therapies in advanced NSCLC patients, reporting the most recent progress in this changing landscape, critically discussing the strengths and weakness of the upcoming strategies and analyzing the current research challenges.

Dr. Umberto Malapelle
Dr. Pasquale Pisapia
Dr. Maria Lucia Reale
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • molecular pathology
  • molecular oncology
  • biomarkers
  • targeted therapies
  • liquid biopsy
  • immunotherapy

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


28 pages, 973 KiB  
Liquid Biopsy Analysis as a Tool for TKI-Based Treatment in Non-Small Cell Lung Cancer
by Karolina Buszka, Aliki Ntzifa, Barbara Owecka, Paula Kamińska, Agata Kolecka-Bednarczyk, Maciej Zabel, Michał Nowicki, Evi Lianidou and Joanna Budna-Tukan
Cells 2022, 11(18), 2871; - 14 Sep 2022
Cited by 6 | Viewed by 3655
The treatment of non-small cell lung cancer (NSCLC) has recently evolved with the introduction of targeted therapy based on the use of tyrosine kinase inhibitors (TKIs) in patients with certain gene alterations, including EGFR, ALK, ROS1, BRAF, and MET [...] Read more.
The treatment of non-small cell lung cancer (NSCLC) has recently evolved with the introduction of targeted therapy based on the use of tyrosine kinase inhibitors (TKIs) in patients with certain gene alterations, including EGFR, ALK, ROS1, BRAF, and MET genes. Molecular targeted therapy based on TKIs has improved clinical outcomes in a large number of NSCLC patients with advanced disease, enabling significantly longer progression-free survival (PFS). Liquid biopsy is an increasingly popular diagnostic tool for treating TKI-based NSCLC. The studies presented in this article show that detection and analysis based on liquid biopsy elements such as circulating tumor cells (CTCs), cell-free DNA (cfDNA), exosomes, and/or tumor-educated platelets (TEPs) can contribute to the appropriate selection and monitoring of targeted therapy in NSCLC patients as complementary to invasive tissue biopsy. The detection of these elements, combined with their molecular analysis (using, e.g., digital PCR (dPCR), next generation sequencing (NGS), shallow whole genome sequencing (sWGS)), enables the detection of mutations, which are required for the TKI treatment. Despite such promising results obtained by many research teams, it is still necessary to carry out prospective studies on a larger group of patients in order to validate these methods before their application in clinical practice. Full article
Show Figures

Figure 1

Back to TopTop